An update on T-cell engagers in follicular lymphoma and large B-cell lymphoma

In this discussion, Loretta Nastoupil, MD, Southwest Oncology, Durango, CO, Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, provide an update on T-cell engagers in non-Hodgkin lymphoma (NHL), specifically in the frontline setting for follicular lymphoma (FL) and large B-cell lymphoma (LBCL). Dr Falchi also highlights safety considerations with these agents, and Dr Westin comments on treatment selection for first-line LBCL in the community setting. This interview took place at the 8th International Workshop on CAR-T and Bispecifics 2026, in Tampa, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.